Inventory of Supplemental Information

1) Supplemental Experimental Procedures
Steven Dowdy (Nagahara et al., 1998)] . A linker (GGSGHSG) was added between the HA-tag and the N-terminal sequence of GIV CT.
TAT-constructs were expressed using BL21(DE3)-pLysS (Invitrogen) and Terrific Broth (BioPioneer) supplemented with additives as per auto-induction protocols outlined by Studier F (Studier, 2005) . Briefly, cultures of bacteria were grown at 300 rpm at 37C for 5 h, then at 25C overnight. Cells were lysed in 10 ml of buffer [50 mM NaH 2 PO 4 , 10 mM Imidazole, 400 mM NaCl, 1% (v:v) Sarkosyl, 1% (v:v) Triton X-100 and protease inhibitor mixture (Roche Diagnostics) (pH 7.4)], sonicated (3 x 30 s), cleared at 12,000 x g for 20 min at 4C and affinitypurified on Ni-NTA agarose resin (Quiagen) (overnight at 4ºC). Proteins were eluted in elution buffer [50 mM NaH 2 PO 4 , 300 mM Imidazole, 400 mM NaCl, pH 7.4] and dialyzed overnight against TBS containing 400 mM NaCl.
Immunofluorescence and confocal microscopy-
Cells were fixed with 3% PFA in PBS for 25 min at room temperature, treated with 0.1 M glycine for 10 min, and subsequently blocked and permeabilized with PBS containing 3% BSA and 0.2% Triton X-100 (or only with 3% BSA in PBS buffer for surface labeling experiments where we used non-permeabilizing conditions) for 45 min at room temperature prior to antibody staining. Dilutions of antibodies are as follows: anti-phospho-GIV-Tyr1764 (1:200) (Ventana/Roche and Spring Biosciences); anti-HA (1:300) (Covance); anti-GFP, mouse antiInsRβ and mouse anti-phospho-IRS1 (1:200) from Santa Cruz Biotechnologies; DAPI 1:1,000 (Molecular Probes); Secondary goat anti-rabbit (594) and goat anti-mouse (488) Alexa conjugated antibodies (1:500) from Molecular Probes. Coverslips were mounted with ProLong Gold (Life Technologies). Cells were imaged on a Leica SPE confocal microscope using a 63x oil objective using 488, 561 and 405 laser lines for excitation. Images were scanned using a line-average of 3. All images were processed using ImageJ software and assembled into figure panels using Photoshop and Illustrator (Adobe).
Cell culture and transfection-
HeLa, Cos7 and L6 cells were cultured according to ATCC guidelines. Low passage (~3 to 8) L6 myoblasts were cultured under non-differentiating conditions in α-MEM (Invitrogen) media supplemented with 10% FBS and differentiated into myotubes by switching to 2% FBS media for 6-7 days.
Transfection was carried out with GeneJuice (Novagen) for DNA plasmids or Oligofectamine (Invitrogen) for siRNA oligos according to manufacturer´s protocols. Silencer negative Control scrambled (Scr) siRNA used as control was purchased from Ambion and the previously validated (Enomoto et al., 2005) GIV siRNA sequence used was custom-ordered from Dharmacon. For TAT-construct transduction, cells were incubated with 300-800 nM of the TAT-proteins for 30 min at 37˚C prior to three washes with PBS and addition of fresh growth media. For assays involving insulin (Novagen) stimulation of TAT-treated cells, such stimulation was carried out 90 min after transduction.
Generation of stable cell lines-
HeLa cell lines stably expressing GIV-3xFLAG-WT, FA or SD mutants were extensively used in previous work (Lopez-Sanchez et al., 2013) . GIV-3xFLAG expression was ~1-2 fold compared to the levels of endogenous GIV. L6 stable cell lines expressing GIV-3xFLAG constructs or L6 stable cell lines expressing Gαi3 WT or Gαi3-W258F (Gαi3-WF) constructs were selected as previously described (Garcia-Marcos et al., 2009; Lopez-Sanchez et al., 2013) with the neomycin analog G418 (Cellgro) at 500 µg/ml. Expression of various GIV constructs in L6 cells were confirmed as ~1-1.5 fold above the endogenous levels by immunoblotting. In all experiments using stable cells, the endogenous GIV was depleted using GIV siRNA such that the cells exclusively expressed the desirable siRNA-resistant GIV mutant at near-physiologic levels. Similarly, Gαi3 expression was confirmed by immunoblotting with anti-Gαi3 antibody and expression was ~1.5-2 fold above the endogenous levels. Control shRNA and GIV shRNA Cos7 stable cell lines were selected with 2 µg/ml of Puromycin (GIBCO). The shGIV sequence used was previously validated (Enomoto et al., 2005) and is identical to the sequence of GIV siRNA.
Depletion of GIV was verified using GIV-CT antibody with an efficiency of ~95%. Treatment with PKCθ pseudo-substrate inhibitor (Santa Cruz Biotechnologies) was performed at 10 µM for 16 h.
Cell lysis and immunoblot analysis-
Whole cell lysates were prepared after washing cells with cold PBS prior to resuspending and boiling them in sample buffer. Cell lysates used as a source of proteins for pulldown assays or immunoprecipitation were prepared by breaking cells during passage through a 28-gauge needle in the presence of lysis buffer [20 mM Hepes (pH 7.2), 5 mM Mg-acetate, 125 mM Kacetate, 0.4% Triton X-100, 1mM DTT, supplemented with sodium orthovanadate (500 μM), phosphatase (Sigma), and Protease (Roche) inhibitor cocktails] at 4C. Crude lysates were cleared of insoluble particles/debris by centrifugation at 10,000 x g for 10 minutes.
Protein samples for immunoblotting were run on SDS/PAGE gels and transferred onto PVDF membranes (Millipore). Membranes were blocked with PBS containing 5% non-fat milk (or with 5% BSA when probing for phosphorylated proteins) before incubation with primary antibodies. GIV was detected using rabbit anti-GIV coiled-coil (Millipore) (1:500); GIV-CT (Santa Cruz Biotechnologies) (1:500); phospho-Tyr1764-GIV (1:500) and phospho-Ser1689-GIV (21 
Glucose uptake assay-
Glucose uptake assays were performed without the use of radioisotopes as described previously (Yamamoto et al., 2006) . HeLa and L6 cells grown in 6-well plates were stimulated with insulin in KRH Buffer [50 mM HEPES, 137 mM NaCl, 4.7 mM KCl, 1.85 mM CaCl 2 , 1.3 mM MgSO 4 , and 0.1% (w/v) BSA-FFA free, pH 7.4]. Cells were incubated with 1 mM 2-deoxyglucose (2-DG) for 20 min, washed, and subsequently lysed with 0.1 N NaOH. The lysates were transfered into eppendorf tubes and samples were incubated in a water bath maintained at 80C for 45 min to degrade endogenous NAD(P)H and NAD(P)
+ . An equal  em = 590 nM) was determined using a Tecan Inifinite M1000 PRO and normalized to total protein, as determined using BCA assay (Thermo Scientific).
GST pulldown assays and immunoprecipitations-
Purified GST-Gαi3, GST-tagged IRS1 domains or GST alone were immobilized on glutathioneSepharose beads (GE Healthcare) for 1 h at room temperature as described before (Garcia- For immunoprecipitation, cell lysates (~2 mg of protein) were incubated for 3 h at 4°C
with 2 g anti-HA, phospho-InsRβ, anti-GFP mAbs or pre-immune control mouse IgG. Protein G Sepharose beads (GE Healthcare) were added and incubated at 4°C for an additional 60 min.
Beads were washed and bound immune complexes were eluted by boiling in Laemmli's sample buffer (Garcia-Marcos et al., 2011; Ghosh et al., 2010; Ghosh et al., 2008) . Diego. Informed written consent was obtained from all subjects after explanation of the protocol.
Data Analysis and Statistics-
All experiments were repeated at least three times, and results were presented either as one representative experiment or as average ± S.D or S.E.M. Statistical significance was assessed with two-tailed Student's t-test. Effect of acute lipotoxicity on the level of GIV mRNA in skeletal muscles of insulin resistant patients. Bar graph displays the fold decrease in the levels of GIV mRNA reported in gene expression analysis carried out on vastus lateralis samples from insulin resistant men before (pre-) and after (post-) meal induced lipotoxicity (Jans et al., 2012) . Briefly, GEO profiles of CCDC88A gene expression in skeletal muscles from insulin resistant men 4 hrs after consumption of meals high in saturated FA (SFA), monounsaturated FA (MUFA), or polyunsaturated FA (PUFA) were analyzed. While GIV mRNA levels are significantly suppressed after SFA and MUFA-rich diets, no significant suppression was noted after ingestion of PUFA-enriched meals. The study also reported that PUFAs, but not SFA and MUFA reduced triacylglycerol-derived skeletal muscle fatty acid uptake, which was accompanied by higher postprandial insulin sensitivity. Our finding that GIV levels are suppressed by SFA and MUFA, but not PUFA are consistent with the fact that SFA and certain MUFAs have been implicated in causing insulin resistance, whereas PUFAs largely do not appear to have adverse effects on insulin action (Lovejoy, 2002) .
2) SUPPLEMENTAL FIGURE LEGENDS
